MATINAS BIOPHARMA HOLDINGS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $11.90 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2022-08-11
- MATINAS BIOPHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was $5.90M, a 25.53% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was $6.00M, a 20.00% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-12-31 was $6.70M, a 6.35% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-09-30 was $6.90M, a 27.78% increase year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was $23.30M, a 4.02% increase from fiscal 2020.
- MATINAS BIOPHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was $22.40M, a 28.74% increase from fiscal 2019.
- MATINAS BIOPHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was $17.40M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2022-06-30 | $5.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $11.90M 10-Q · filed 2022-08-11 | $18.60M derived: sum of 3 quarters · filed 2022-08-11 | $25.50M derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | $6.00M 10-Q · filed 2022-05-12 | $12.70M derived: sum of 2 quarters · filed 2022-05-12 | $19.60M derived: sum of 3 quarters · filed 2022-05-12 | $24.30M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-12-31 | $6.70M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | $13.60M derived: sum of 2 quarters · filed 2022-03-11 | $18.30M derived: sum of 3 quarters · filed 2022-08-11 | $23.30M 10-K/A · filed 2022-03-11 |
| 2021-09-30 | $6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $11.60M derived: sum of 2 quarters · filed 2022-08-11 | $16.60M 10-Q · filed 2021-11-08 | $22.90M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-06-30 | $4.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $9.70M 10-Q · filed 2022-08-11 | $16.00M derived: sum of 3 quarters · filed 2022-08-11 | $21.40M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $5.00M 10-Q · filed 2022-05-12 | $11.30M derived: sum of 2 quarters · filed 2022-05-12 | $16.70M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $6.30M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | $11.70M derived: sum of 2 quarters · filed 2022-03-11 | $22.40M 10-K/A · filed 2022-03-11 | |
| 2020-09-30 | $5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $16.10M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $10.70M 10-Q · filed 2021-08-10 | |||
| 2019-12-31 | $17.40M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |